These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 68276)

  • 41. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of exogenous estrogens on catabolism of VLDL in cholesterol-fed rabbits.
    Kushwaha RS; Hazzard WR
    Am J Physiol; 1981 Nov; 241(5):E372-7. PubMed ID: 7304741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The formation of deoxycholic acid in patients with type II and IV hyperlipoproteinaemia.
    Carella M; Einarsson K; Hellström K
    Atherosclerosis; 1976; 24(1-2):293-9. PubMed ID: 182186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic defect in type-III hyperlipoproteinaemia.
    Ballantyne D; Ballantyne FC; Stromberg P
    Lancet; 1977 Sep; 2(8037):556-7. PubMed ID: 95753
    [No Abstract]   [Full Text] [Related]  

  • 45. Hypertriglyceridaemia secondary to liver disease.
    Müller P; Felin R; Lambrecht J; Agostini B; Wieland H; Rost W; Seidel D
    Eur J Clin Invest; 1974 Dec; 4(6):419-28. PubMed ID: 4374360
    [No Abstract]   [Full Text] [Related]  

  • 46. Triglyceride-production rates in patients with type-4 hypertriglyceridaemia.
    Kaye JP; Galton DJ
    Lancet; 1975 May; 1(7914):1005-7. PubMed ID: 48674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amelioration of hypertriglyceridaemia by progestational drugs in familial type-V hyperlipoproteinaemia.
    Glueck CJ; Brown WV; Levy RI; Greten H; Fredrickson DS
    Lancet; 1969 Jun; 1(7609):1290-1. PubMed ID: 4182181
    [No Abstract]   [Full Text] [Related]  

  • 48. Gallbladder disease in hyperlipoproteinaemia.
    Einarsson K; Hellström K; Kallner M
    Lancet; 1975 Mar; 1(7905):484-7. PubMed ID: 46958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.
    Shimizu-Albergine M; Basu D; Kanter JE; Kramer F; Kothari V; Barnhart S; Thornock C; Mullick AE; Clouet-Foraison N; Vaisar T; Heinecke JW; Hegele RA; Goldberg IJ; Bornfeldt KE
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34491909
    [TBL] [Abstract][Full Text] [Related]  

  • 50. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.
    Li Z; Shue F; Zhao N; Shinohara M; Bu G
    Mol Neurodegener; 2020 Nov; 15(1):63. PubMed ID: 33148290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.
    Basu D; Bornfeldt KE
    Front Endocrinol (Lausanne); 2020; 11():504. PubMed ID: 32849290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.
    Chait A; Ginsberg HN; Vaisar T; Heinecke JW; Goldberg IJ; Bornfeldt KE
    Diabetes; 2020 Apr; 69(4):508-516. PubMed ID: 32198194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypertriglyceridaemia in diabetes.
    Smellie WS
    BMJ; 2006 Dec; 333(7581):1257-60. PubMed ID: 17170417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes.
    Murdoch SJ; Boright AP; Paterson AD; Zinman B; Steffes M; Cleary P; Edwards K; Marcovina SS; Purnell JQ; Brunzell JD;
    Atherosclerosis; 2007 May; 192(1):138-47. PubMed ID: 16740268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver.
    Ockner RK; Lysenko N; Manning JA; Monroe SE; Burnett DA
    J Clin Invest; 1980 May; 65(5):1013-23. PubMed ID: 7364935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Degradation of lipoproteins by human monocyte-derived macrophages. Evidence for two distinct processes for the degradation of abnormal very-low-density lipoprotein from subjects with type III hyperlipidaemia.
    Soutar AK; Knight BL
    Biochem J; 1984 Feb; 218(1):101-11. PubMed ID: 6324746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia.
    Rall SC; Weisgraber KH; Innerarity TL; Mahley RW
    J Clin Invest; 1983 Apr; 71(4):1023-31. PubMed ID: 6300187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.
    Stalenhoef AF; Malloy MJ; Kane JP; Havel RJ
    J Clin Invest; 1986 Sep; 78(3):722-8. PubMed ID: 3745433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
    Weintraub MS; Eisenberg S; Breslow JL
    J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Chappell DA
    J Clin Invest; 1988 Aug; 82(2):628-39. PubMed ID: 2841358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.